Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).

@article{Harada2012PhaseIR,
  title={Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).},
  author={Hideyuki Harada and Takashi Seto and Satoshi Igawa and Asuka Tsuya and Mayuko Wada and Kyoichi Kaira and Tateaki Naito and Kazushige Hayakawa and Tetsuo Nishimura and N. Masuda and Nobuyuki Yamamoto},
  journal={International journal of radiation oncology, biology, physics},
  year={2012},
  volume={82 5},
  pages={1777-82}
}
PURPOSE To investigate the safety and efficacy of concurrent vinorelbine and thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS Eligible patients were 71 years of age or older with unresectable Stage III NSCLC. Patients were treated with thoracic radiotherapy (60 Gy) and concurrent vinorelbine (20 mg/m(2) in Level 1 and 25 mg/m(2) in Level 2) on Days 1 and 8 every 3 weeks for two cycles, followed by adjuvant vinorelbine… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS